ICS 205-930 ([IH
-indol-3-carbonic-acid tropineester hydrochloride, Sandoz, Basle, Switzerland), is a recently synthesised compound which is a potent and highly selective antagonist of 5-hydroxytryptamine (5-HT) at excitatory receptors located on peripheral neurones. These low affinity 5-HT-M receptors, which have recently been called 5-HT3-receptors, are widely distributed through the peripheral nervous system and also occur in the enteric nervous system where they control the release of substance P, which activates the smooth muscle cells of the gut wall. 23 Data obtained in animal studies indicate that 5-HT3-receptors may play an important role in the regulation of gastrointestinal motility. In vitro, ICS 205-930 and another selective, but less potent 5 The test doses were given in single blind fashion, and their order of administration was determined by a randomisation list (Latin square design). As the analysis of each gastric emptying study was done by one of the investigators who did not know which substance was infused, the study was in effect double blind.
Gastric emptying was measured with a previously described scintigraphic technique8 starting at 0900 hours and continuing for at least two hours. Each subject had fasted from 22 00 hours the previous day. The solid test meal consisted of a pancake containing 8-6 g of protein, 40-2 g of carbohydrate and 8-4 g of fat, labelled with 9 MBq 'Tc-tin colloid. The subject was seated, leaning backwards at an angle of 60°to avoid overprojection of stomach and intestines, and radioactivity was measured by a ventrally positioned large field of view scintillation camera. Data were acquired in frame mode in a 64 by 64-matrix format with a time resolution of one minute. The data were corrected for subject movement, radionuclide decay and tissue attenuation using previously described methods.9 Time activity curves (expressed as percentage retention of the meal v time) were derived for the stomach and the remainder of the abdomen. From each gastric emptying curve the duration of the lag phase before food emptied from the stomach, the linear emptying rate after the lag phase and the time for 50% emptying were derived for subsequent statistical analysis.89 Each gastric emptying test was analysed and interpreted without knowledge of the study medication.
A standard 12-lead electrocardiogram was done immediately before and after each study and during each intravenous infusion the electrocardiogram was monitored continuously. Other safety evaluations included continuous monitoring of pulse rate, and measurement of blood pressure at least every five minutes and body temperature at least every 15 minutes from the start of the intravenous infusion until the completion of the test. On each study day, a thorough clinical examination, haematological and biochemical blood screen and a standard urinalysis were done before and at the end of the test. Each subject was asked to notify the investigators immediately of the occurrence of any possible adverse events during, or after each study period.
Gastric emptying data were analysed using the Wilcoxon's rank-sum test for paired data and changes in cardiovascular, haematological, and biochemical parameters were assessed using analysis of variance.
Results
All subjects tolerated the study well and no significant effects on cardiovascular, haematological or In all subjects gastric emptying of the solid meal was characterised by an initial lag phase, followed by an emptying phase which closely approximated a linear pattern. The duration of the lag phase was less (p<0.01), the linear emptying rate was faster (p<0-02) and the 50% emptying time was less (p<0-01) after 20 mg of ICS 205-930 compared with placebo (Table) . After the 10 mg ICS 205-930 the lag phase was less (p<0.04) and there were nonsignificant trends (p<0-055) for a more rapid linear emptying phase and a shorter 50% emptying time, compared with placebo (Table) . There was no significant difference between the 10 mg and 20 mg ICS 205-930 for any of the three parameters.
Discussion
Previous studies have confirmed that ICS 205-930 is a potent and selective antagonist of neuronal 5-HT3 receptors. '2 Because the affinity of the drug for other common neurotransmitter receptors is negligible, no adverse cardiovascular or central nervous system effects have been reported. ICS 205-930 was well tolerated and effective in 11 patients treated with the drug to prevent cisplatin induced vomiting.'0 ICS 205-930 has been reported to be effective in the treatment of secretory diarrhoea associated with the carcinoid syndrome, but one of the three patients in this study developed pyrexia and a skin rash which resolved on discontinuation of the drug." Our study also indicates that intravenous doses of ICS 205-930 are generally well tolerated. The symptoms of constipation and abdominal fullness observed by two subjects were mild, but may have been related to the use of the drug.
The results of our study suggest that 5-HT3-receptors may be involved in the regulation of gastric 
